眾生藥業(002317.SZ):眾生睿創穫發明專利證書
格隆匯11月13日丨眾生藥業(002317.SZ)公佈,近日,公司控股子公司眾生睿創收到中華人民共和國國家知識產權局頒發的發明專利證書。發明名稱:酪氨酸激酶抑制劑及包含該酪氨酸激酶抑制劑的藥物組合物;專利號:ZL201680019729.0
該專利是眾生睿創開發的具有治療特發性肺纖維化(IPF)和惡性腫瘤雙重作用創新藥ZSP1603項目的化合物專利,屬於該項目的核心專利。ZSP1603是國內同靶點第一個獲批臨牀用於治療IPF的小分子創新藥物。目前,ZSP1603項目已完成I期臨牀試驗並獲得臨牀試驗總結報告,臨牀試驗工作正按計劃積極推進中。
本次ZSP1603項目化合物專利獲得國家知識產權局的授權,是繼該項目晶型核心專利獲得美國專利授權後,又一項核心專利獲得專利授權,該專利授權有利於公司進一步完善知識產權保護體系,發揮自主知識產權優勢,保持技術領先地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.